ARVINAS, INC. Operating Income
ARVINAS, INC. (ARVN) reported Operating Income of $164.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- ARVINAS, INC. operating income (loss) for the quarter ending 2026-06-30 was $164.10M.
- ARVINAS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$63.80M, a 189.36% decline year-over-year.
- ARVINAS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$74.60M.
- ARVINAS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$43.80M.
- ARVINAS, INC. operating income (loss) for fiscal 2025 was -$118.50M.
- ARVINAS, INC. operating income (loss) for fiscal 2024 was -$250.20M.
- ARVINAS, INC. operating income (loss) for fiscal 2023 was -$401.50M.
- ARVINAS, INC. operating income (loss) for fiscal 2022 was -$263.20M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $164.10M 10-Q · filed 2026-08-04 | $100.30M 10-Q · filed 2026-08-04 | $25.70M derived: sum of 3 quarters · filed 2026-08-04 | -$18.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$63.80M 10-Q · filed 2026-05-11 | -$138.40M derived: sum of 2 quarters · filed 2026-05-11 | -$182.20M derived: sum of 3 quarters · filed 2026-05-11 | -$253.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$74.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$118.40M derived: sum of 2 quarters · filed 2026-02-24 | -$189.90M derived: sum of 3 quarters · filed 2026-08-04 | -$118.50M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | -$43.80M 10-Q · filed 2025-11-05 | -$115.30M derived: sum of 2 quarters · filed 2026-08-04 | -$43.90M 10-Q · filed 2025-11-05 | -$102.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$71.50M 10-Q · filed 2026-08-04 | -$100.00K 10-Q · filed 2026-08-04 | -$58.30M derived: sum of 3 quarters · filed 2026-08-04 | -$118.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $71.40M 10-Q · filed 2026-05-11 | $13.20M derived: sum of 2 quarters · filed 2026-05-11 | -$47.10M derived: sum of 3 quarters · filed 2026-05-11 | -$95.60M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$58.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$118.50M derived: sum of 2 quarters · filed 2026-02-24 | -$167.00M derived: sum of 3 quarters · filed 2026-02-24 | -$250.20M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | -$60.30M 10-Q · filed 2025-11-05 | -$108.80M derived: sum of 2 quarters · filed 2025-11-05 | -$192.00M 10-Q · filed 2025-11-05 | -$357.40M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | -$48.50M 10-Q · filed 2025-08-06 | -$131.80M 10-Q · filed 2025-08-06 | -$297.10M derived: sum of 3 quarters · filed 2026-02-24 | -$371.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | -$83.30M 10-Q · filed 2025-05-01 | -$248.60M derived: sum of 2 quarters · filed 2026-02-24 | -$322.50M derived: sum of 3 quarters · filed 2026-02-24 | -$397.10M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | -$165.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$239.20M derived: sum of 2 quarters · filed 2026-02-24 | -$313.80M derived: sum of 3 quarters · filed 2026-02-24 | -$401.50M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | -$73.90M 10-Q · filed 2024-10-30 | -$148.50M derived: sum of 2 quarters · filed 2024-10-30 | -$236.20M 10-Q · filed 2024-10-30 | -$311.80M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | -$74.60M 10-Q · filed 2024-07-30 | -$162.30M 10-Q · filed 2024-07-30 | -$237.90M derived: sum of 3 quarters · filed 2025-02-11 | -$302.20M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | -$87.70M 10-Q · filed 2024-05-07 | -$163.30M derived: sum of 2 quarters · filed 2025-02-11 | -$227.60M derived: sum of 3 quarters · filed 2025-02-11 | -$293.40M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | -$75.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$139.90M derived: sum of 2 quarters · filed 2025-02-11 | -$205.70M derived: sum of 3 quarters · filed 2025-02-11 | -$263.20M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | -$64.30M 10-Q · filed 2023-11-07 | -$67.20M 10-Q · filed 2022-11-09 | -$130.10M derived: sum of 2 quarters · filed 2023-11-07 | -$187.60M 10-Q · filed 2023-11-07 | -$195.40M 10-Q · filed 2022-11-09 | -$235.30M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | -$65.80M 10-Q · filed 2023-08-08 | -$68.30M 10-Q · filed 2022-08-04 | -$123.40M 10-Q · filed 2023-08-08 | -$128.20M 10-Q · filed 2022-08-04 | -$171.00M derived: sum of 3 quarters · filed 2024-02-27 | -$218.30M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | -$57.70M 10-Q · filed 2023-05-05 | -$60.00M 10-Q · filed 2022-05-05 | -$105.20M derived: sum of 2 quarters · filed 2024-02-27 | -$152.50M derived: sum of 3 quarters · filed 2024-02-27 | -$204.40M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | -$47.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$94.80M derived: sum of 2 quarters · filed 2024-02-27 | -$146.70M derived: sum of 3 quarters · filed 2024-02-27 | -$188.40M 10-K · filed 2024-02-27 | -$195.30M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | -$47.30M 10-Q · filed 2022-11-09 | -$47.33M 10-Q · filed 2021-11-03 | -$99.20M derived: sum of 2 quarters · filed 2022-11-09 | -$140.90M 10-Q · filed 2022-11-09 | -$140.85M 10-Q · filed 2021-11-03 | -$180.06M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-06-30 | -$51.90M 10-Q · filed 2022-08-04 | -$51.88M 10-Q · filed 2021-08-05 | -$93.50M 10-Q · filed 2022-08-04 | -$93.52M 10-Q · filed 2021-08-05 | -$132.76M derived: sum of 3 quarters · filed 2023-02-23 | -$164.50M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | -$41.70M 10-Q · filed 2022-05-05 | -$41.65M 10-Q · filed 2021-05-04 | -$80.86M derived: sum of 2 quarters · filed 2023-02-23 | -$112.60M derived: sum of 3 quarters · filed 2023-02-23 | -$139.09M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | -$39.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$70.90M derived: sum of 2 quarters · filed 2023-02-23 | -$97.39M derived: sum of 3 quarters · filed 2023-02-23 | -$120.80M 10-K · filed 2023-02-23 | -$124.86M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$31.75M 10-Q · filed 2021-11-03 | -$58.23M derived: sum of 2 quarters · filed 2021-11-03 | -$81.64M 10-Q · filed 2021-11-03 | -$104.43M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | -$26.48M 10-Q · filed 2021-08-05 | -$49.90M 10-Q · filed 2021-08-05 | -$72.69M derived: sum of 3 quarters · filed 2021-08-05 | -$67.18M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | -$23.41M 10-Q · filed 2021-05-04 | -$46.20M derived: sum of 2 quarters · filed 2021-05-04 | -$40.70M derived: sum of 3 quarters · filed 2021-05-04 | -$59.12M derived: sum of 4 quarters · filed 2021-05-04 | ||||
| 2019-12-31 | -$22.79M 10-K · filed 2020-03-16 | -$17.29M derived: sum of 2 quarters · filed 2020-11-05 | -$35.71M derived: sum of 3 quarters · filed 2020-11-05 | -$51.50M 10-K · filed 2022-02-28 | -$51.52M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $5.50M 10-Q · filed 2020-11-05 | -$12.92M derived: sum of 2 quarters · filed 2020-11-05 | -$28.73M 10-Q · filed 2020-11-05 | -$45.68M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$18.42M 10-Q · filed 2020-08-04 | -$34.24M 10-Q · filed 2020-08-04 | -$51.18M derived: sum of 3 quarters · filed 2020-08-04 | -$65.24M derived: sum of 4 quarters · filed 2020-08-04 | ||||
| 2019-03-31 | -$15.81M 10-Q · filed 2020-04-28 | -$32.76M derived: sum of 2 quarters · filed 2020-04-28 | -$46.82M derived: sum of 3 quarters · filed 2020-04-28 | -$55.33M derived: sum of 4 quarters · filed 2020-04-28 | ||||
| 2018-12-31 | -$16.94M 10-K · filed 2020-03-16 | -$31.00M derived: sum of 2 quarters · filed 2020-03-16 | -$39.52M derived: sum of 3 quarters · filed 2020-03-16 | -$43.80M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | -$14.06M 10-K · filed 2020-03-16 | -$22.58M derived: sum of 2 quarters · filed 2020-03-16 | -$26.86M 10-Q · filed 2019-11-04 | -$32.17M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-06-30 | -$8.52M 10-K · filed 2020-03-16 | -$12.80M 10-Q · filed 2019-08-05 | -$18.11M derived: sum of 3 quarters · filed 2020-03-16 | -$24.52M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-03-31 | -$4.28M 10-K · filed 2020-03-16 | -$9.59M derived: sum of 2 quarters · filed 2020-03-16 | -$16.00M derived: sum of 3 quarters · filed 2020-03-16 | -$22.73M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2017-12-31 | -$5.31M 10-K · filed 2019-03-26 | -$11.72M derived: sum of 2 quarters · filed 2019-03-26 | -$18.44M derived: sum of 3 quarters · filed 2019-03-26 | -$24.76M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | -$6.41M 10-K · filed 2019-03-26 | -$13.14M derived: sum of 2 quarters · filed 2019-03-26 | -$19.45M 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | -$6.72M 10-K · filed 2019-03-26 | -$13.04M derived: sum of 2 quarters · filed 2019-03-26 | ||||||
| 2017-03-31 | -$6.32M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |